Jefferies Group's GALT Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 12,188 shares of Galectin Therapeutics Inc. (GALT) worth $34,005, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Jefferies Group has maintained this position in GALT for several quarters, showing initial confidence in the investment. Largest reduction occurred in Q1 2026, reducing 4,247 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Galectin Therapeutics (GALT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Galectin Therapeutics (GALT) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -4,247 | Reduce 25.84% | 12,188 | $2.79 |
| Q4 2025 | -865 | Reduce 5.00% | 16,435 | $4.16 |
| Q3 2025 | +17,300 | New Buy | 17,300 | $4.24 |
Jefferies Group's Galectin Therapeutics Investment FAQs
Jefferies Group first purchased Galectin Therapeutics Inc. (GALT) in Q3 2025, acquiring 17,300 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Galectin Therapeutics Inc. (GALT) for 3 quarters since Q3 2025.
Jefferies Group's largest addition to Galectin Therapeutics Inc. (GALT) was in Q3 2025, adding 17,300 shares worth $73,266.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 12,188 shares of Galectin Therapeutics Inc. (GALT), valued at approximately $34,005.
As of the Q1 2026 filing, Galectin Therapeutics Inc. (GALT) represents approximately 0.00% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Galectin Therapeutics Inc. (GALT) was 17,300 shares, as reported at the end of Q3 2025.